Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 26INDUSTRY 12NIH 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Small Cell Lung Carcinoma 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1Advanced Rare Tumours 1

Interventions

Gene Expression Profiling 7Polymerase Chain Reaction 5Filgrastim 5Doxorubicin 5Radiotherapy 3Gemcitabine 3Cyclophosphamide 3Amplified Fragment Length Polymorphism Analysis 3Vincristine 2Reverse Transcriptase Polymerase Chain Reaction 2Radiosurgery 2Microarray Analysis 2Interferon-alpha 2Immunohistochemistry 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Dactinomycin 2DNA Methylation 2Cytogenetic Analysis 2Chemotherapy, Adjuvant 2Carboplatin 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1siltuximab 1peginterferon alfa-2b 1pegfilgrastim 1aldesleukin 1Traumeel S 1Sunitinib 1Spectrum Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Kidney Neoplasms × Sunitinib × Clear all
NCT01164228 2023-06-15

Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery

Eastern Cooperative Oncology Group

Phase 2 Completed
87 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡